Findings in case study of man being treated for non-small-cell lung cancer
FRIDAY, Nov. 17, 2017 (HealthDay News) — Overdosing of erlotinib may be associated with rapid onset of conjunctivitis, according to a case report published online Oct. 25 in the Journal of Clinical Pharmacy and Therapeutics.
P. Sun, from the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, and colleagues describe the case of a 72-year-old male with metastatic non-small-cell lung cancer who developed conjunctivitis after accidentally taking erlotinib at a dosage of 300 mg/day for four days.
The authors report that the patient had been taking erlotinib at the prescribed dose of 150 mg/day for 17 days. The conjunctivitis was successfully treated symptomatically while erlotinib was discontinued for seven days. The adverse effect did not recur when the patient resumed taking erlotinib 150 mg/day, suggesting the ocular change was related to the overdosing of erlotinib.
“Awareness and close monitoring of this adverse effect are helpful for doctors and pharmacists to identify inadvertent drug overdose,” the authors write. “Patients should be provided comprehensive education before receiving targeted therapy.”
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV 
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines 
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine 
Achieving PSA <0.2 ng/mL Improves Survival in Metastatic Castration-Sensitive Prostate Cancer 
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer 
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment 
Indefinite-Duration Maintenance Therapy No Better Than Fixed-Duration Therapy in Multiple Myeloma 
